The lower-than-expected revenue projections for both Q1 and FY24 indicate potential short-term financial challenges for Bionano Genomics. Restructuring debt and phasing out non-core products are strategic moves to stabilize the company, but these actions, along with the revenue miss, could negatively impact investor sentiment in the short term. However, the plan to install 80-100 new OGM systems in 2024 suggests a positive outlook for growth, which might mitigate some negative perceptions.